Neptune Technologies (NASDAQ:NEPT) suffered a major setback in a tragic explosion to its main production facility in Quebec on Nov. 8. Since then and up until today, trading in the company's shares had been frozen. Markets reacted by sending shares down 24%, reflecting the major production setback from the destroyed facility. The loss will impact the company's main product, a krill-oil-based nutritional supplement. However, one of its subsidiaries has aspirations to compete with fish-oil based pharmaceuticals from companies such as Amarin (NASDAQ:AMRN) and GlaxoSmithKline (NYSE:GSK)
Brenton Flynn has no positions in the stocks mentioned above. Max Macaluso has no positions in the stocks mentioned above. The Motley Fool owns shares of GlaxoSmithKline. Motley Fool newsletter services recommend GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
